1. NuVasive reported better-than-expected second quarter financials, with its minimally invasive spine surgery product sales up 6.4 percent year-over-year to around $203 million. Earnings per share expanded 322 percent to $0.20 for the second quarter.
2. There is an increasing demand for spine surgery and spine products, and NuVasive is making gains in market share. The company estimates full year sales at $810 million, which is up 6.2 percent.
3. Earnings growth for the full year is expected to top 74 percent over 2014.
4. The company settled with the Department of Justice in an alleged false or improper claims case and the final amount NuVasive paid, $13.5 million, was less than some projected. The company can now focus more on growth.
5. As the third largest player in the market, NuVasive still has room for growth. The company will likely report significant profit growth in the coming year, according to the report.
More articles on orthopedic devices:
Smith & Nephew to build US headquarters in Fort Worth
Nevro announces positive results from SENZA system study
Is Stryker next for a big transaction?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
